Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

5.720 -0.050 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus: Chiseling Away At The Aesthetic Market ↗
Via Talk Markets
News headline image
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
From Evolus
Via Business Wire
News headline image
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
From Evolus
Via Business Wire
News headline image
Recap: Evolus Q4 Earnings ↗
 
Via Benzinga
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
From Evolus, Inc.
Via Business Wire
News headline image
EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024 ↗
EOLS stock results show that Evolus beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Evolus Reports First Quarter 2024 Results and Provides Business Update
From Evolus
Via Business Wire
News headline image
Earnings Outlook For Evolus ↗
 
Via Benzinga
News headline image
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. 
Via Investor's Business Daily
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday! 
Via InvestorPlace
News headline image
Evolus to Report First Quarter Financial Results on May 7, 2024
From Evolus
Via Business Wire
News headline image
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Evolus
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023 ↗
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
From Evolus
Via Business Wire
News headline image
Earnings Scheduled For March 7, 2024 ↗
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
News headline image
Evolus Announces Results from European Head-to-Head Filler Trial
From Evolus
Via Business Wire
News headline image
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
From Evolus
Via Business Wire
News headline image
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings ↗
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped... 
Via Benzinga
News headline image
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported... 
Via Benzinga
Topics Stocks
News headline image
Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker ↗
Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.